×

Cardio3 BioSciences Announces Results of Annual Shareholder Assembly 2015 and Confirmation of Name Change to Celyad

MONT-SAINT-GUIBERT, Belgium, May 5, 2015 (GLOBE NEWSWIRE) -- Cardio3 BioSciences ("the Company") (Brussels:CARD) (Paris:CARD) a leader in the discovery and development of engineered cell therapies, today announced that all resolutions presented at the Company's Annual Shareholder Assembly were duly passed at the meeting, which was held today at 09:00 CET.



As a result, the Company's proposed name change to "Celyad" is now confirmed, effective immediately. The new corporate website is available online at www.celyad.com. Furthermore, as of 09:00 CET on 6 May 2015, the Company will trade on the Euronext Brussels and Paris regulated markets under the symbol CYAD, replacing former symbol CARD. No specific action is required from our shareholders following this symbol change.

The Company is also pleased to announce that copies of the 2014 Annual Report and Accounts will be made available to shareholders on the "Investors" section of the Company's website at www.celyad.com, and paper copies will be made available upon request to the Company.

For more information, please contact:

Celyad SA
Christian Homsy, CEO
Julie Grade, Corporate Communications Manager
www.celyad.com
Tel: +32 10 39 41 00
jgrade@celyad.com
For Europe: Consilium Strategic Communications
Amber Bielecka, Chris Welsh, Laura Thornton
Tel : +44 20 3709 5700
celyad@consilium-comms.com
For the U.S: The Ruth Group
Lee Roth (Investors), Kirsten Thomas (Media)
Tel: +1 646 536 7012 / 7014
celyad@theruthgroup.com

To subscribe to Celyad's newsletter, visit www.celyad.com.

Follow us on Twitter @CelyadSA

About Celyad

Founded in 2007, and based in Belgium, Celyad is a leader in engineered cell therapy with clinical programs initially targeting indications in cardiology and oncology. Celyad is developing its lead cardiovascular disease product candidate, C-Cure®, for the treatment of ischemic heart failure, and has completed enrolment of a Phase III trial in Europe and Israel. In addition, the Company is developing a novel portfolio of CAR T-cell therapies that utilize human Natural Killer cell receptors for the treatment of numerous blood and solid cancers. Its lead oncology product candidate, NKG2D CAR T-cell, entered a Phase I clinical trial in April 2015.

Celyad's shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CYAD.

To learn more about Celyad, please visit www.celyad.com

Forward looking statements

In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of clinical trials, including Phase III clinical trials for C-Cure® and Phase I clinical trial for NKG2D CAR T-Cell additional clinical results validating the use of adult autologous stem cells to treat heart failure and CAR T-cell autologous therapy to treat cancer; satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; obtaining, maintaining and protecting intellectual property, our ability to enforce our patents against infringers and defend our patent portfolio against challenges from third parties, competition from others developing products for similar uses, our ability to manage operating expenses, and our ability to obtain additional funding to support our business activities and establish and maintain strategic business alliances and business initiatives. Any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.

C3BS-CQR-1, C-Cure, NKG2D CAR T-Cell, C-Cathez, OnCyte, Celyad, Cardio3 BioSciences and the Cardio3 BioSciences, Celyad, C-Cathez, CHART-1, CHART-2 and OnCyte logos are signs internationally protected under applicable Intellectual Property Laws. Mayo Clinic holds equity in Celyad as a result of intellectual property licensed to the company.

Source: Celyad; Cardio3 BioSciences